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ABSTRACT
ZNF224 is a Krüppel-associated box-containing zinc-finger protein which 
represses gene transcription by interacting with various co-repressors. However, 
its consensus DNA sequences and target genes are not fully identified. In this study, 
we identified and characterized consensus DNA sequences containing 5‘-CAGC-3’ 
recognized by ZNF224 through ChIP-sequencing, which further confirmed by ELISA, 
SPR, qPCR, and luciferase activity assay. ZNF224 increased miR-663a transcription 
by binding to miR-663a promoter, which in turn binds to 3’ UTR of p53 and p21 
to decrease their expression. miR-663a antagonist abolished ZNF224-mediated 
suppression of p21 and p53, resulting in the enhanced apoptosis by CPT. The analyses 
using human breast ductal carcinoma tissues exhibited that the expression of ZNF224 
and miR-663a was increased in cancer compared to non-cancer region. Consequently, 
ZNF224 increases cell survival and decreases apoptosis by decreasing the expression 
of p53 and p21 via miR-663a as a transcriptional activator. Taken together, we 
identified and characterized DNA binding element of ZNF224, and its target genes, 
miR-663a, which provides a novel insight in the down-regulation of p21 and p53 via 
miR-663a by ZNF224 in breast cancer.
INTRODUCTION
Transcription factor (TF) represses or activates 
transcription of target genes by binding to its DNA binding 
elements during a variety of cellular processes. Krüppel-
like associated box-zinc finger proteins (KRAB-ZFPs), 
is a member of DNA binding protein family [1]. KRAB-
ZFPs have conserved KRAB domain at N-terminal region 
and a C2H2-type zinc-finger motif at C-terminal region 
[2]. KRAB-ZFPs have one or more KRAB A boxes, and/
or a KRAB B box, or a SCAN-domain, a leucine-rich 
region that is found in a small subset of KRAB-ZFPs [3-
4]. Recently, it has been known that KRAB domain of 
ZFP binds to corepressor proteins and/or TFs via protein-
protein interactions, resulting in transcriptional repression 
of target genes [5-6]. KRAB-ZFPs forms complex with 
KRAB-associated protein 1 (KAP1), one of corepressor 
as well as a mediator of chromatin remodeling complex, 
then binds to its corresponding DNA consensus sequence 
to silence gene expression [7-9].
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ZNF224 is a transcription factor composed of 
KRAB A domain, KRAB B domain at N-terminal 
region, and 19 tandemly repeated C2H2-type zinc finger 
motifs [10]. ZNF255, an alternative splice variant of 
ZNF224, lacks the KRAB domain, but contains 19 zinc-
finger domains [11]. There are some differences in the 
localization. ZNF224 is homogenously distributed in 
the nucleus, whereas ZNF255 localized in subnuclear 
structures in association with nucleoli, and also in the 
cytoplasm [12]. The nuclear interaction of ZNF224 
with Wilms’ tumor suppressor gene (WT1) increases the 
expression of WT1 target genes, whereas ZNF255 mainly 
participates in RNA maturation and processing, together 
with WT1 [13].
ZNF224 functions as a transcriptional repressor 
by forming a complex with KAP1 and a type II protein 
arginine methyltransferase (PRMT5), leading to 
transcriptional repression of aldolase A gene [10, 14-
16]. In addition, ZNF224 represses transcription of 
mitochondrial citrate carrier gene [17]. Interestingly, 
ZNF224 acts as a co-activator of WT1 in the regulation 
of proapoptotic and antiapoptotic genes, including Bax, 
Bak, Vitamin D receptor (VDR), bag3, and A1/Bfl1 
[5]. Moreover, DEP domain containing 1(DEPDC1) 
suppressed A20 transcription by ZNF224. However, upon 
disruption of ZNF224/DEPDC1 complex, the A20 mRNA 
expression is increased [18]. These results suggest that 
ZNF224 functions as an oncoprotein or tumor suppressor 
in interacting protein dependent manner or in cancer type 
dependent manner.
In this study, we first determined whether ZNF224 
could function as an oncogenic protein. In addition, we 
tried to identify target genes and DNA consensus sequence 
recognized by ZNF224 in MCF-7 cells. We performed 
ChIP sequencing and then, identified and characterized 
DNA consensus sequence. Interestingly, we found that 
this consensus sequence recognized by ZNF224 is present 
within - 500 bp of miR-663a promoter, and examined 
whether ZNF224 increases or decreases expression of 
miR-663a. Furthermore, we assessed the expression of 
ZNF224 and miR-663a using human breast cancer tissues.
RESULTS
ZNF224 increases cell growth and drug 
resistance in MCF-7
To determine whether ZNF224 functions as an 
oncogene or tumor suppressor, ZNF224 was transfected 
into MCF-7 cells and subjected to colony forming assay. 
ZNF224 over-expression increased colony forming 
ability about 3 folds, which was decreased about 4 folds 
upon si-RNA knock-down of ZNF224 (Figure 1A-1D). 
These results suggest that ZNF224 could function as an 
oncogene. Since over-expression of oncogene induces 
resistance to apoptosis [19], we generated ZNF224 
over-expressing cell line and ZNF224 knock-down 
cell line, respectively, as described in the Methods 
section, and examined cell survival against CPT, a DNA 
damaging agent, using iCelligence, and apoptosis using 
FACS. ZNF224 over-expression showed enhanced 
proliferation compared to E.V control (Figure 2A), 
whereas the ZNF224 knock-down showed the reduced 
cell proliferation compared to control shRNA (Figure 2B). 
ZNF224 over-expression delayed apoptosis compared 
to E.V control upon CPT treatment (Figure 2A), which 
increased apoptosis upon knock-down of ZNF224 using 
shRNA (Figure 2B). In addition, apoptosis analysis using 
FACS showed that subG1 population induced by CTP in 
ZNF224 over-expression cell line was lower than E.V 
control (Figure 2C), whereas subG1 population of ZNF224 
knock-down cell line was higher than control shRNA 
(Figure 2D). PARP1 cleavage assay further clearly showed 
that ZNF224 over-expression cell line is more resistant to 
CPT-induced apoptosis compared to E.V control, and vice 
versa, upon shRNA knock-down of ZNF224 (Figure 2E 
and 2F).
Determination of DNA consensus sequences and 
its target gene recognized by ZNF224
As described above, it is postulated that ZNF224 
can function as an oncogene in MCF-7 cells. However, 
its DNA consensus sequence or target genes are not 
fully unveiled. Thus we tried to identify DNA consensus 
sequence and its target genes of ZNF224 through ChIP 
sequencing. Using the HOMER, we identified 10,185 
peaks of ZNF224 in HEK293, and there was a tendency 
for ZNF224 enriched regions within 1 kb of the 5′ gene 
boundary to cluster around transcriptional start site (TSS) 
(Supplementary Figure 1A). The genes containing ZNF224 
enriched regions near (<1 kb) are listed in Supplementary 
Table 1. In addition, as shown in Supplementary Figure 
1B, the ZNF224 signals at promoters including 1 kb 
upstream and downstream of the TSS occupy about 
12% of total peaks in HEK293. To determine the DNA 
consensus sequence recognized by ZNF224, 13,561 peaks 
validated by the MACS program were analyzed using 
HOMER, and further processed using Structural Time 
series Analyser, Modeller and Predictor (STAMP). We 
found a putative motif containing the sequence 5′-CAGC-
3′ as shown in Figure 3A. We then synthesized a variety 
of 5′-biotinylated hairpin duplex oligo DNA (Figure 3B), 
and purified FLAG-ZNF224 from HEK293 cells. To 
confirm the binding of ZNF224, biotinylated oligo DNA 
was fixed to streptavidin coated plate, and then purified 
FLAG-ZNF224 was added to each well. Then the bound 
FLAG-ZNF224 was detected with anti-FLAG antibody. 
As shown in Figure 3C, the sequences containing 5′-
CAGC-3′ showed significantly higher binding affinity 
compared to control or mutant oligo DNAs. In addition, 
to further confirm the binding of ZNF224 to oligo DNA, 
Oncotarget31179www.impactjournals.com/oncotarget
we performed the SPR assay. Quantitation of the binding 
affinity of ZNF224 to oligo DNA containing 5′-CAGC-
3' showed that the ZNF224 bound to CAGCTTC (KD= 
1.25±0.06x10-6 M), CAGCGTC (KD=2.0±0.1x10
-6 M), 
and GCAGCAA (KD=0.42±0.03x10
-6 M), whereas oligo 
DNA containing mutant sequence didn’t show any 
binding affinity (data not shown). To determine whether 
the oligo DNA sequence containing 5′-CAGC-3′ can 
function as promoter, we constructed luciferase vector 
containing 5′-CAGCGTC-3′ sequence in the promoter as a 
representative. As shown in Figure 3D, ZNF224 increased 
luciferase activity in a dose-dependent manner, confirming 
that DNA sequence containing 5′-CAGC-3′ functions 
as DNA consensus sequence recognized by ZNF224 
in the promoter. Then we searched for DNA sequence 
containing 5′-CAGC-3′ among promoter enriched tags 
of ChIP sequencing and summarized top 10 candidates 
(Supplementary Figure 2A), and 7 of 10 candidate genes 
shows agreement with top 10 ChIP tags (Supplementary 
Figure 2B).
ZNF224 decreases expression of p53 and p21 via 
miR-663a
It has been known that miR-663a was highly 
expressed in lung and prostate cancer [20-21]. The 
increased expression level of miR-663a is associated 
with poor prognosis [20], and the down-regulation of 
miR-663a sensitized chemoresistant breast cancer cells 
to cyclophosphamide and docetaxel [22]. In addition, 
Figure 1: ZNF224 increases colony forming ability of MCF-7 cells. A. MCF-7 cells were transfected with empty vector (E.V) 
or FLAG-ZNF224 (2 μg) and subjected to colony forming assay for 14 days (*, vs. E.V). B. The over-expression of FLAG-ZNF224 was 
confirmed by RT-PCR and immunoblot. C. MCF-7 cells were transfected with control or ZNF224 targeting si-RNA (20 nM), and colony 
forming ability was examined (**, vs. si-control). D. The knock-down of ZNF224 was examined by RT-PCR and immunoblot. GAPDH 
and tubulin were used as loading control. Data represent the mean ± SEM of three independent experiments. *P < 0.01, and **P < 0.01.
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Figure 2: ZNF224 increases cell growth and apoptosis resistance. A and B. ZNF224 over-expression cell line or ZNF224 knock-
down cell line was seeded into iCelligence chamber and cultured for 10 h. Then CPT (0.1 μM) was treated, and cell growth was analyzed. 
Data are from at least three independent experiments (n=3). C and D. ZNF224 over-expression cell line or ZNF224 knock-down cell line 
was treated with CPT (0.1 μM) for 24 h, and subG1 population was analyzed as described in the Methods section. Data are from at least 
three independent experiments (n=3). E and F. ZNF224 over-expression cell line or ZNF224 knock-down cell line was treated with CPT 
(0.1 μM) in a time-dependent manner. Protein extracts were subjected to SDS-PAGE to analyze PARP1 cleavage. Tubulin was used as a 
loading control.
Figure 3: ZNF224 DNA binding motif characterization. A. DNA motif within ZNF224 enriched region from ChIP sequencing. 
B. Hair-pin loop structure containing 5′-CAGC-3′ sequence. C. Biotinylated oligo DNAs (5 μM) were fixed to streptavidin coated 96 well 
plates and purified FLAG-ZNF224 (50 ng) was loaded to each well. The bound FLAG-ZNF224 was detected with anti-FLAG antibody, 
and developed as described in the Methods section. Data are from at least three independent experiments (n=3). D. pGL3 vector containing 
(200 ng) 5′-CAGCTTC-3′ sequence with empty vector (E.V) or FLAG-ZNF224 (50, 100, and 200 ng) was transfected to MCF-7 cells for 
24 h, and luciferase activity assay was performed. Luciferase activity was normalized to Renilla (100 ng) luciferase activity. The expression 
of FLAG-ZNF224 was detected with anti-FLAG antibody (inset). Tubulin was used as a loading control. Data are from at least three 
independent experiments (n=3).
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miR-663a regulates cancer cell proliferation by targeting 
TGFβ 1 and p21 [21, 23]. Furthermore, the expression of 
miR-663a was increased in nasopharyngeal carcinoma 
[23]. However, in other cancers, including gastric cancer, 
leukemia, non-small cell lung cancer, pancreatic cancer, 
multiple myeloma, and glioblastoma, miR-663a functions 
as a tumor suppressor [24-31]. Of note, miR-663a was 
shown to have two putative DNA consensus sequences 
recognized by ZNF224 in -500 bp region as shown in 
Figure 4A. To further confirm the binding of ZNF224 to 
the promoter of miR-663a, we transfected FLAG-ZNF224, 
performed ChIP assay, and PCR. As shown in Figure 4B 
and 4C, anti-FLAG antibody precipitated the promoter 
DNA of miR-663a, but not mock antibody. In addition, 
qRT-PCR analysis in MCF-7 showed that ZNF224 
increased transcription level of miR-663a in a dose-
dependent manner (Figure 4D). These results suggest that 
ZNF224 increases transcription of miR-663a by binding to 
the promoter containing 5′-CAGC-3′ sequence.
miR-663a binds to the 3′ UTR of p21 to down-
regulate its expression in nasopharyngeal carcinoma 
[23], and we also found that p53 contains miR-663a 
binding sequence in 3′ UTR (Figure 5A). Therefore, we 
constructed luciferase reporter vectors and examined 
whether the miR-663a could down-regulate the 
expressions of p53 and p21. As shown in Figure 5B, 
miR-663a decreased luciferase activity of p53-3′ UTR-
wild type, and p21-3′ UTR-wild type, but not of p53-3′ 
UTR-mutant, and p21-3′ UTR-mutant, agreement with 
previous report [23]. In addition, miR-663a antagonist 
abrogated the decrease of luciferase activity by miR-
663a. Furthermore, ZNF224 decreased luciferase activity 
of p53-3′ UTR-wild type, and p21-3′ UTR-wild type in a 
dose-dependent manner, but not of p53-3′ UTR-mutant, 
and p21-3′ UTR-mutant (Figure 5C). To confirm whether 
the decreased luciferase activity of p53-3′ UTR and 
p21-3′ UTR is mediated by miR-663a via ZNF224, we 
examined luciferase activity after transfection of ZNF224 
and miR-663a antagonist. The over-expression of ZNF224 
significantly decreased luciferase activity of p53-3′ UTR-
wild type, and p21-3′ UTR-wild type, but not of p53-3′ 
UTR-mutant, and p21-3′ UTR-mutant (Figure 5D). In 
addition, miR-663a antagonist significantly abolished the 
decrease of luciferase activity by ZNF224 (Figure 5D), 
suggesting that ZNF224 can down-regulate the expression 
of p53 and p21 by increasing the transcription of miR-
663a.
Next, we examined whether ZNF224 could 
decrease the transcript and protein level of p53 and 
p21 via miR-663a. miR-663a transfection efficiently 
decreased protein level as well as transcript level of 
p21 and p53 (Figure 6A and 6B). In addition, miR-
Figure 4: ZNF224 binds to miR-663a promoter. A. miR-663a promoter sequence analysis. Two regions containing 5′-CAGC-3′ 
sequence were found within - 500 bp. Arrow indicates primer binding sites for PCR. B and C. FLAG-ZNF224 was transfected to HEK293 
cells, and ChIP assay using normal or FLAG IgG was carried out. PCR was performed using miR-663a promoter primers between -350 
bp and -89 bp. In addition, ChIPed DNA was analyzed with qPCR. Data are from at least three independent experiments (n=3). D. FLAG-
ZNF224 (0.5 1, and 2 μg) was transfected to MCF-7 cells in a dose-dependent manner for 24 h, and miR-663a transcript level was examined 
by qRT-PCR. miR-663a transcript level was normalized to U6 RNA. Data are from at least three independent experiments (n=3).
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Figure 5: ZNF224 regulates promoter activity of p21 and p53 via miR-663a. A. the putative miR-663a binding sequences for 
the p53 and p21 3′ UTRs. Human p53 and p21 3’ UTR fragments containing either the wild type (WT) or mutant (MT) miR-663a binding 
sequences were cloned downstream of the luciferase reporter gene in the psiCHECK vector. B. MCF-7 cells were co-transfected with 
psiCHECK vector (200 ng) and Renilla vector (100 ng) in the presence or absence of miR-663a (20 nM), and in the presence or absence of 
miR-663a antagonist (40 nM). Luciferase activity was normalized to Renilla luciferase activity. Data represent the mean ± SEM of three 
independent experiments (*, vs. luc-p53 or luc-p21 #1 or luc-p21 #2/LNA-control (ctrl); **, vs. luc-p53 or luc-p21 #1 or luc-p21 #2/LNA-
ctrl/miR-663a). C. MCF-7 cells were co-transfected with psiCHECK vector (200 ng) and Renilla vector (100 ng) in the presence or absence 
of FLAG-ZNF224. Luciferase activity was normalized to Renilla luciferase activity. The expression of FLAG-ZNF224 was confirmed 
using anti-FLAG antibody (inset). Tubulin was used as a loading control. Data represent the mean ± SEM of three independent experiments 
(**, vs. luc-p53 or luc-p21 #1 or luc-p21 #2/FLAG-ZNF224 (-)). D. MCF-7 cells were co-transfected with psiCHECK vector (200 ng) 
and Renilla vector (200 ng) in the presence or absence of FLAG-ZNF224, and in the presence or absence of miR-663a antagonist (40 
nM). Luciferase activity was normalized to Renilla luciferase activity. The expression of FLAG-ZNF224 was confirmed using anti-FLAG 
antibody (inset). Tubulin was used as a loading control. Data represent the mean ± SEM of three independent experiments (*, vs. luc-p53 
or luc-p21 #1 or luc-p21 #2/LNA-ctrl; **, vs. luc-p53 or luc-p21 #1 or luc-p21 #2/FLAG-ZNF224/LNA-ctrl). *P < 0.001, **P < 0.01.
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663a increased colony forming ability of MCF-7 cells 
(Figure 6C), whereas miR-663a antagonist abrogated 
the decreased expression of p21 and p53, and increased 
colony formation induced by miR-663a (Figure 6A-
6C). Since the decreased expression level of p21 and 
p53 induces apoptosis resistance [32], cell growth and 
apoptosis were analyzed after treatment of CPT. miR-
663a transfection increased cell growth of MCF-7 
cells and induced resistance of apoptosis by CPT, and 
vice versa, upon transfection of miR-663a antagonist 
(Figure 6D). In addition, transfection with ZNF224 
decreased not only mRNA levels of p21 and p53 but 
also their protein levels, and increased transcript level 
of miR-663a, whereas miR-663a antagonist abrogated 
the effect of ZNF224, suggesting that the decreased 
expression of p21 and p53 by ZNF224 was mediated by 
miR-663a (Figure 6E and 6F). In addition, the increased 
colony forming ability and cell growth induced by 
ZNF224 over-expression was abolished by transfection 
of miR-663a antagonist (Figure 6G and 6H). Moreover, 
miR-663a antagonist abrogated the enhanced cell 
growth induced by ZNF224 over-expression, leading 
to sensitization of apoptosis resistance (Figure 6H). 
Si-RNA transfection of ZNF224 increased transcript 
levels of p21 and p53, but not miR-663a transcript level 
(Figure 6I). Western blot analysis showed that knock-
down of ZNF224 using si-RNA increased the expression 
level of p53, but not p21 (Figure 6J).
Figure 6: ZNF224 controls cell growth by regulating expressions of p21 and p53 via miR-663a. A and B. MCF-7 cells were 
transfected with LNA-ctrl or miR-663a (20 nM) in the presence or absence of miR-663a antagonist (40 nM) as indicated. The expression 
of p21 and p53 was examined by qRT-PCR and immunoblot, respectively. GAPDH and tubulin were used as loading control in qRT-PCR 
and immunoblot, respectively. Data are from at least three independent experiments (n=3). C and D. In addition, colony forming ability 
was analyzed (*, vs. LNA-ctrl; **, vs. miR-663a) and subjected to iCelligence for the growth analysis in the presence or absence of CPT 
(0.1 μM). E and F. MCF-7 cells were transfected with FLAG-ZNF224 (2 μg) in the presence or absence of miR-663a antagonist (40 nM). 
The expression of p21, p53, miR-663a, and ZNF224 was examined by qRT-PCR and immunoblot, respectively. GAPDH and U6 RNA were 
used as loading control for mRNA and microRNA, respectively, in qRT-PCR, and tubulin was used as a loading control for immunoblot. 
Data are from at least three independent experiments (n=3). G and H. In addition, colony forming ability was analyzed (#, vs. EV; †, vs. 
ZNF224) and subjected to iCelligence for the growth analysis in the presence or absence of CPT (0.1 μM). I and J. MCF-7 cells were 
transfected with control or ZNF224 si-RNA (20 nM), and the expression of p21, p53, miR-663a, and ZNF224 was examined by qRT-PCR 
and immunoblot, respectively (**, vs. control si-RNA). GAPDH and U6 RNA were used as loading control for mRNA and microRNA, 
respectively, in qRT-PCR, and tubulin was used as a loading control for immunoblot. Data represent the mean ± SEM of three independent 
experiments. *P < 0.01, **P < 0.01, # P < 0.01, and † P < 0.01.
Oncotarget31184www.impactjournals.com/oncotarget
Next, we examined the transcript levels of 
ZNF224, miR-663a, p21, and p53 in ductal carcinoma of 
breast cancer patients. H&E and immunohistochemical 
staining showed that ZNF224 expression level was 
increased in cancer region compared to non-cancer 
region (15 of 18 cases) (Figure 7A and 7B), whereas 
ZNF224 mRNA expression was increased only in 8 
cases of 18 cases (Figure 7C). In addition, miR-663a 
transcript level was increased in 7 of 14 cases, and 
p53 mRNA level was decreased in 8 cases of 16 cases 
(Figure 7D and 7E), whereas p21 mRNA was not 
detected (data not shown). Among the tested tissues, 
3 cases (16.6%) showed that the increase of ZNF224 
transcript level is correlated with increased miR-663a 
RNA (rs = -0.4862, p=0.0389) and decreased p53 mRNA 
(rs = -0.3446, p=0.046).
DISCUSSION
Although ZNF224, one of KRAB-ZFPs, has been 
known as a transcriptional repressor of aldolase A, 
mitochondrial citrate carrier, and A20 [10, 14, 17-18], 
ZNF224 acts as co-activator of WT1 to increase the 
gene expression, including Bax, Bak, Vitamin D receptor 
(VDR), bag3, and A1/Bfl1 [33]. DNA consensus sequences 
of KRAB-ZFPs have been known [34-37], however, their 
consensus sequences don’t show any similarity between 
KRAB-ZFPs. Therefore, to unveil the precise mechanism 
of ZNF224 as an oncogene or tumor suppressor gene, and 
because it is not known even whether ZNF224 binds to 
which sequences, we tried to identify target genes and 
DNA consensus sequence recognized by ZNF224. We 
found that DNA consensus sequences containing 5’-
Figure 7: Expression analyses in human breast cancer. A and B. Tissues of breast cancer patients were divided into non cancer and 
cancer region, and H&E staining and immunohistochemistry using anti-ZNF224 antibody was carried out. C-E. Total RNAs were isolated 
from cancer and non-cancer regions of breast cancer patients, and the expression of ZNF224, miR-663a, and p53 was examined by qRT-
PCR (n=14-18). GAPDH and U6 were used as loading control in ZNF224 and p53, and miR-663a, respectively.
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CAGC-3’ is critical to the binding of ZNF224, which 
was further characterized by ELISA, SPR and luciferase 
activity assay. This DNA consensus sequence is different 
in length from other consensus sequences that show over 
10 bases.
miR-663a, identified as a target gene of ZNF224, 
exhibits a differential function in different cancer types, 
as a tumor suppressor or as an oncogene [20-29, 31]. In 
this study, we identified miR-663a as an oncogene in 
breast cancer by directly down-regulating p21 and p53. 
Why miR-663a shows differential activity in a variety of 
cancer may be due that the mRNA copy number and genes 
of miR-663a target is different in cancer. In addition, it 
might be possible that the order of target genes could 
be determined by base pairing affinity with miR-663a 
because base paring between mircro-RNA and its target 
gene varies from 4 base pairs to 9 base pairs.
The over-expression of ZNF224 directly increased 
transcription level of miR-663a. However, knock-down 
of ZNF224 using si-RNA didn’t decrease miR-663a 
transcript level, and increased p21 and p53 mRNA 
levels, whereas p53 expression is increased (Figure 
6I and 6J); this is because the reduced expression of 
ZNF224, a transcription factor, might indirectly increase 
p53 expression by affecting transcriptional network. It 
has been known that miR-125b, miR-130b, and miR-
155 promote tumor growth by decreasing tumor protein 
53-induced nuclear protein 1 (TP53INP1) that increases 
p53 expression [38-41]. We found that the knock-down of 
ZNF224 using si-RNA decreased expression of miR-125b, 
miR-130b, and miR-155 in microarray (Supplementary 
Figure 3), and increased TP53INP1α expression in 
immunoblot. In addition, the over-expression of FLAG-
ZNF224 decreased expression of TP53INP1α, but not 
TP53INP1β (Supplementary Figure 4A and 4B), which 
shows a possibility that ZNF224 could decrease p53 
expression by TP53INP1α via miR-125b, miR-130b, and 
miR-155 as well. In addition, DNA consensus sequences 
containing 5′-CAGC-3′ was found in the promoter of p21 
and p53, and PCR after ChIP using anti-FLAG antibody 
showed that ZNF224 could bind to the promoter of p21 
and p53, suggesting that ZNF224 might function as a 
transcriptional repressor of p21 and p53 (Supplementary 
Figure 5A and 5B). Furthermore, CPT treatment induced 
degradation of ZNF224 in a time dependent manner, 
and after then, the mRNA levels of p21 and p53 were 
increased (Supplementary Figure 6A and 6B), which 
further suggests a possibility that ZNF224 might function 
as a transcriptional repressor of p21 and p53.
Interestingly, CPT treatment decreased expression 
level of ZNF224 in 6 h, and scarcely detectable after 24 
h (Figure 2E and 2F), which suggest that DNA damage 
signal induces transcriptional repression or protein turn-
over of ZNF224. However, qRT-PCR of ZNF224 after 
CPT treatment did not induce any change of ZNF224 
mRNA level (data not shown), which suggests a possibility 
that DNA damage signal may induce degradation of 
ZNF224 by post-translational modification such as 
ubiquitination. It is well known that KRAB domain and 
it’s neighboring amino acid sequences are critical to 
ubiquitination of KRAB-ZFPs [42-43]. Interestingly, 
KAP1 binds to KRAB domain of KRAB-ZFPs to function 
as an ubiquitin E3 ligase [43-44]. In another study, it has 
been reported that the expression of KAP1 and KRAB-
ZFPs was increased in breast carcinoma, and sumoylated-
KAP1 protects the KRAB-ZFPs from proteasomal 
degradation, which promotes proliferation and metastatic 
progression of breast cancer cells [45]. Therefore, whether 
DNA damage signal induces degradation of ZNF224 in a 
KAP1 dependent manner or by another mechanism needs 
further investigation.
In addition, immunohistochemical staining showed 
that ZNF224 expression level was increased in most 
cancer region (15 of 18 cases) (Figure 7A and 7B), 
whereas ZNF224 mRNA expression was increased only 
in 8 cases of 18 (Figure 7C). Addison et al reported 
that mRNA expression level of ZNF224 is decreased in 
cancer compared to normal area [45]. This result also 
suggests a possibility that ZNF224 could be stabilized by 
posttranslational modification, not transcription level, in 
cancer. Therefore, the stable over-expression of ZNF224 
in breast cancer might induce apoptosis resistance, leading 
to cancer progression by down-regulating the expression 
of p21 and p53 via miR-663a.
In summary, ZNF224 containing KRAB domain 
functions as an oncogene in breast cancer by regulating 
p21 and p53 via micro-RNA. It is not surprising any more 
that ZNF224 functions as a tumor suppressor or oncogene 
in cancer because there is a possibility that the function 
of ZNF224 depends on co-activator or repressor bound 
to KRAB domain of ZNF224. Therefore, it is postulated 
that there is a co-activator bound to KRAB domain of 
ZNF224, and it needs their identification and further study 
to diversify the role of ZNF224.
MATERIALS AND METHODS
Cell culture
HEK293 (Human embryonic kidney cell line) 
and MCF-7 (Human adenoma breast cancer cell line) 
cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Hyclone, Utah, USA) supplemented 
with 10% fetal bovine serum (FBS, Hyclone), 1% 
penicillin/streptomycin (Hyclone, Utah, USA) at 37°C 
in a humidified 5% CO2 incubator. For transfection, 
plasmid DNA constructs were transfected into cells by 
polyethylenimine (PEI, Polysciences, Inc., PA, USA) 
according to the manufacturer’s protocol. To obtain 
overexpressed ZNF224 stable clones, we transfected 
MCF-7 cells with CMV 3XFlag-ZNF224 G418-
selectable plasmid that kindly provided by Dr. Paola 
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Costanzo (University of Naples Federico II, Italy) [10]. 
Transfected cells were grown and selected in the medium 
supplemented with 80 μg/ml of G418 (Duchefa, Haarlem, 
Netherlands). The MCF-7 cells stably overexpressing 
CMV 3xFLAG-ZNF224 were analyzed by Western blot 
using anti-FLAG M2 antibody (Sigma Aldrich, MO, 
USA). To generate ZNF224 knock-down stable cell line, 
we transfected MCF-7 cells with ZNF224 shRNA plasmid 
(Santa Cruz Biotechnology, CA, USA). The transfected 
cells were grown and selected in the medium containing 
with 10 μg/ml puromycin (Sigma Aldrich, MO, USA). The 
stable knock-down of ZNF224 was confirmed by Western 
blot and quantitative RT-PCR.
RNAi study
MCF-7 cells were transfected with 20 nM ZNF224 
si-RNA mixture (#1 5′-CUC AAG ACU UGG UGA 
UAA ATT-3′, #2 5′-CGA UGU GAU ACG UGU GAU 
ATT-3′, #3 5′-GGA AAG GGC UAC AAU AGU ATT-3′, 
Santa Cruz Biotechnology) for 48 h or 72 h, 20 nM miR-
663a (5′-AGG CGG GGC GCC GCG GGA CCG C-3′ 
duplex, Bioneer, Korea) for 48 h or 72 h, and 50 nM miR-
663a antagonist (Bioneer, Korea), for 48 h or 72 h using 
Lipofectamine 2000 (Invitrogen, Paisley, UK) according 
to the manufacturer’s protocol.
Western blot
For immunoblot, cells were lysed with lysis buffer 
(50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Triton 
X-100, 10% glycerol, 1 mM EDTA, 1 mM PMSF, 10 mM 
NaF, 0.1 mM NaVO
3
). The whole cell lysates (30 μg) were 
subjected to SDS-PAGE, and transferred to polyvinyldene 
fluoride membrane (PVDF, Millipore, MA, USA). The 
membrane was blocked with TBS (20 mM Tris-HCl, 
pH 7.4, 150 mM NaCl) containing 5% skim milk and 
0.2% Tween-20 at room temperature for 1 h, followed 
by incubation with ZNF224 specific antibody (1:1000, 
Abcam, Cambridge, UK), M2 anti-FLAG (1:3,000, 
Sigma Aldrich, MO, USA), anti-p21 (1:1,000, Santa Cruz 
Biotechnology, CA, USA), anti-p53 (1:1,000, Santa Cruz 
Biotechnology, CA, USA), anti-PARP1 (1:1,000, Santa 
Cruz Biotechnology, CA, USA) and anti-alpha-tubulin 
antibody (1:20,000). The secondary antibodies were anti-
mouse IgG HRP (1:25,000, Thermo Scientific, MA, USA) 
or anti-rabbit IgG HRP (1:30,000, Thermo Scientific, MA, 
USA). The membrane was developed using enhanced 
chmiluminescence (ECL) solution (Abclon, Korea).
Cell growth and drug resistance analysis
For analysis of cell growth and drug resistance, each 
of stable clones (5×104 cells) was seeded onto 8-E plate 
(ACEA, CA, USA) and cultured in a humidified 5% CO2 
incubator. After 10 h, cells were treated with DMSO or 0.1 
μM CPT, and further cultured for 24 h. During cell culture, 
cell growth was monitored in real time using iCelligence 
system (ACEA, CA, USA).
Flow cytometry
Apoptosis by CPT was measured by flow cytometry. 
Cells (2.5×106) were seeded onto 100 mm dish and 
cultured for 24 h. Then, DMSO or CPT (0.1 μM) was 
added to each group of cells. After 24 h, cells harvested 
and fixed in cold 70% ethanol for 16 h. After rehydration 
with 1x cold PBS, cells were treated with RNaseA (50 
μg/ml, Roche, Mannheim, Germany) and propidium 
iodide (100 μg/ml, Sigma Aldrich, MO, USA). The DNA 
contents were analyzed by flow cytometry (CUBE6, 
PARTEC, Germany).
Chromatin immnunoprecipitation assay and 
sequencing
HEK293 cells were transfected with CMV 
3xFLAG-ZNF224 plasmid (6 μg). Chromatin 
immunoprecipitation was performed as described 
previously [46]. Briefly, cells were allowed to crosslink 
with 1% formaldehyde for 10 minutes at room 
temperature (RT). The cell pellets were incubated in 200 
μl of sonication buffer (50 mM HEPES, pH 7.9, 140 mM 
NaCl, 1 mM EDTA, 0.1% Na-deoxycholate, 0.1% SDS, 
1% Triton X-100 and PIC). The cell lysate was sonicated 
for 70 seconds (10 sec pulse and 60 sec rest), and DNA 
lengths were sheared to between 200 and 1,000 bp. The 
mixture of nucleic acid and protein was incubated with 
M2 anti-FLAG antibody (Sigma Aldrich, MO, USA) or 
normal mouse IgG antibody (Santa Cruz Biotechnology, 
CA, USA), followed by immunoprecipitation using 
Protein A and G agarose bead mixture (Invitrogen, 
Paisley, UK). The protein–DNA complexes were 
separated from the beads by elution buffer (50 mM Tris-
HCl, pH 8.0, 1 mM EDTA, 1% SDS, 50 mM NaHCO
3
) 
and heated at 65°C for 5 h with protease K to reverse the 
formaldehyde crosslink. Finally, the DNA was purified 
with the PCR Clean-up Kit (Promega, WI, USA). ChIPed 
DNA was further processed to prepare sequencing library 
with some modifications [47]. DNA fragments were 
end-repaired, dA-tailed, and ligated with Genomic DNA 
Adapters provided by Illumina. Adapter-ligated DNA 
fragments were purified and amplified with 20 cycles 
of PCR. Gel extraction was performed to isolate 200-
400 bp of PCR products. Libraries were sequenced by 
Illumina Genome Analyzer IIx. Alignment of sequences 
reads were performed using Illumina’s CASAVA pipeline 
(v1.8.2). Uniquely aligned tags allowing 2 mismatches 
were used for the further analyses. Raw sequencing 
reads were investigated for quality using FASTQC tool. 
The reads were aligned to the human genome build 
hg18 (NCBI 36) using CASAVA v1.6.0 with default 
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parameters. Total mapped tag counts for ZNF224 were 
4.09 million. The sequencing data was deposited into the 
Gene Expression Omnibus (GEO) at the National Center 
for Biotechnical Information (NCBI) (GSE73947). To 
identify peaks enriched with FLAG-ZNF224, MACS 
(Model-based Analysis for ChIP-Seq) ver. 1.4.0 was used 
with the following options; --tsize=36 --pvalue=1e-4 
--mfold=30 --bw=100. Alternatively, HOMER 
(Hypergeometric Optimization of Motif EnRichment) 
ver. 4.1 was used with the following options; -fragLength 
200 -gsize 2700000000 -center. Annotating peaks in 
genome was performed with HOMER. A histogram was 
created by calculating read densities around individual 
transcription start site (TSS) in each 50 bps. DAVID 
was used to investigate Gene Ontology terms enriched 
with genes containing any peaks within 1 kb from their 
TSSs. Discovery of enriched motifs in peaks were also 
performed with HOMER.
ZNF224 purification from HEK293
HEK293 cells were transfected with CMV 
3xFLAG-ZNF224 plasmid. After 36 h, protein extracts 
were prepared with lysis buffer (50 mM Tris-HCl, pH 
7.6, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 
mM EDTA, 1 mM PMSF, 10 mM NaF, 0.1 mM NaVO
3
). 
The protein extracts (10 mg) were incubated with anti-
FLAG M2 magnetic bead (Sigma Aldrich, MO, USA) at 
4°C. The precipitated bead-protein complex was washed 
1x cold PBS containing 1 mM PMSF, and eluted with 
elution buffer (0.1 M glycin, pH 2.5). After purification, 
FLAG-ZNF224 proteins were dialyzed against 1x PBS, 
and stored at -70°C (Supplementary Figure 7).
ELISA
To determine DNA consensus sequence recognized 
by ZNF224, streptavidin coated plate (Thermo Scientific, 
MA, USA) was washed with 200 μl of wash buffer 
(25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% BSA, 
0.05% Tween-20), and then 100 μl of the 5′-biotinylated 
oligo DNA (5 μM) was added to each well. 50 ng of 
purified FLAG-ZNF224 proteins in 1X PBS containing 
20% glycerol was added to each well and incubated 
for 2 h at RT, and plate was washed three times with 
wash buffer. Anti-FLAG antibody (1 μg/ml) diluted 
in wash buffer was added to each well (100 μl/well), 
and further incubated for 2 h at RT. After washing, the 
horseradish peroxidatse (HRP)-conjugated goat anti-
mouse IgG (1:5,000) diluted in 25 mM Tris-HCl, pH 
7.6, 150 mM NaCl, 0.5% BSA, 0.05% Tween-20 was 
added to each well and further incubated for 30 min. 
After washing the plate with washing buffer, 3, 3′, 5, 5′ - 
tetramethylbenzidine solution was added for 15 min. The 
signal was read at 450 nm (BMG Labtech, Ortenberg, 
Germay).
Luciferase activity assay
MCF-7 cells (2.5×105) were seeded onto 12-well 
plates and transfected with the pGL3-basic luciferase 
reporter vectors (200 ng) containing triple repeat of 
CAGCTTC sequence with Renilla vector (100 ng) in 
the presence or absence of FLAG-ZNF224 (200 ng) and 
cultured for 24 h. To investigate the effect of ZNF224 
and miR-663a, MCF-7 cells were transfected with 
psiCHECK™ vectors (200 ng) containing p21 3’ UTR or 
p53 3’ UTR with Renilla vector (200 ng) in the presence 
of FLAG-ZNF224 (200 ng) or miR-663a (20 nM) for 24 
h. Then cells were treated with miR-663a inhibitor (50 
nM, Bioneer, Korea) for 48 h. Luciferase activity was 
measured with the Dual-Luciferase Reporter Assay System 
(Promega, WI, USA) and quantified using GloMax® 
(Promega, WI, USA) according to the manufacturer’s 
instructions.
Surface plasmon resonance
Surface plasmon resonance (SPR) analysis was 
performed using a SR7500DC (Reichert, NY, USA). 
FLAG-ZNF224 proteins (50 μg) were immobilized 
to CMDH chips (Reichert, NY, USA) according to 
manufacturer’s protocols. Oligo DNA (0, 0.625 μM, 1.25 
μM, 2.5 μM, 5.0 μM, and 10 μM) was allowed to pass as 
an analyte in 1x PBS. KD value was evaluated using the 
Scrubber2 software.
Quantitative RT-PCR
To analyze gene expression, total RNA was extracted 
using TRIzol reagent (Invitrogen, Paisley, UK) according 
to the manufacturer’s protocol. cDNA was prepared by 
reverse transcription with 500 ng of total RNA, and each 
gene transcript was amplified by PCR with their specific 
primers (Supplementary Table 2). Quantitative RT-PCR 
was performed with Power SYBR Green PCR Master 
Mix® (ABI, CA, USA) and StepOne 48 well real time 
PCR system (ABI, CA, USA). To further confirm ChIP 
sequencing results, Re-ChIP was performed and ChIPed 
DNA was amplified by PCR with their specific primers 
(Supplementary Table 3). Each Ct value was normalized 
to the input samples, ΔCt[Ct(IP) – Ct(Input)]. ChIP signals 
were calculated as fold value of the input 2-[ΔΔCt]. Each 
ChIP assay was repeated at least three times.
Immunohistochemical staining
Written informed consent was obtained from 
breast cancer patients, and this study was approved 
by Institutional Review Board of Yonsei University 
Severance Hospital (4-2015-0168). Specimens were ductal 
carcinoma between stage 1 and 2. Immunohistochemical 
staining was performed as described previously [48]. 
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Sections (5 μm) were stained for 1 h at RT with anti-p53 
and anti-ZNF224 antibodies diluted with 1/50. Staining 
was detected with the Ultra View universal DAB detection 
kit (Ventana, AZ, USA) according to the manufacturer’s 
instrutions. The nuclei were counterstained with Mayer’s 
haematoxylin (Dako, Glostrup, Denmark)
Statistics
The results are expressed mean ± S.D. or mean ± 
SEM. The student’s t test was performed to determine 
the statistical significance of group all the experiments 
performed. p<0.05 was considered statistically significant.
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